<DOC>
	<DOCNO>NCT01666795</DOCNO>
	<brief_summary>The objective human study evaluate association specificity anti-platelet autoantibody response IVIG treatment .</brief_summary>
	<brief_title>Autoantibody Specificity Response IVIG ITP</brief_title>
	<detailed_description>Immune thrombocytopenia ( ITP ) common autoimmune bleed disorder , platelet surface GPIIb/IIIa GPIb/IX two frequently target autoantigens . Our previous study animal model ITP demonstrate intravenous immunoglobulin G ( IVIG ) could protect anti-GPIIb/IIIa-mediated thrombocytopenia fail ameliorate ITP induce anti-GPIb/IX antibody . The objective human study evaluate association specificity anti-platelet autoantibody response IVIG treatment .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>( 1 ) diagnosis ITP base presence isolate thrombocytopenia absence obvious initiate and/or underlying cause thrombocytopenia accordance recently release international consensus guideline , ( 2 ) diagnosis establish 4 week prior initiation IVIG treatment , ( 3 ) age ≥ 18 year , ( 4 ) platelet count ≤ 20 × 109/L , ( 5 ) bleed score ≥ 9 time admission accord clinical scoring system describe Khellaf et al . assess severity hemorrhage . history ITPspecific treatment administer prior concomitantly IVIG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>